[Image Sergey Nivens/Adobe Stock]
The life sciences sector experienced an explosive boom during the pandemic’s early phase, followed by a slight cooling in funding in 2022. Despite this, the Barnes & Thornburg law firm’s 2023 Investment Funds Outlook report indicates that opportunities within the sector remain plentiful.John E. Kelly, a partner in the firm and chair of the firm’s Healthcare Industry Group, emphasized a greater need for balance, long-term planning and investor responsiveness in the life sciences sector. “There’s just a bit of a balancing act going on in the sector, with a focus on innovative therapies and delivery platforms such as gene and cell therapies,” he explained.
The report highlights substantial capital flow into life sciences funds, largely targeting innovative fields such as AI-powered drug discovery, precision medicine, gene therapy and cell t…